Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton, Alberta, Canada.
Department of Medicine, Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
JAMA. 2023 Jun 13;329(22):1967-1980. doi: 10.1001/jama.2023.7560.
Approximately 20% to 30% of patients admitted to an intensive care unit have sepsis. While fluid therapy typically begins in the emergency department, intravenous fluids in the intensive care unit are an essential component of therapy for sepsis.
For patients with sepsis, intravenous fluid can increase cardiac output and blood pressure, maintain or increase intravascular fluid volume, and deliver medications. Fluid therapy can be conceptualized as 4 overlapping phases from early illness through resolution of sepsis: resuscitation (rapid fluid administered to restore perfusion); optimization (the risks and benefits of additional fluids to treat shock and ensure organ perfusion are evaluated); stabilization (fluid therapy is used only when there is a signal of fluid responsiveness); and evacuation (excess fluid accumulated during treatment of critical illness is eliminated). Among 3723 patients with sepsis who received 1 to 2 L of fluid, 3 randomized clinical trials (RCTs) reported that goal-directed therapy administering fluid boluses to attain a central venous pressure of 8 to 12 mm Hg, vasopressors to attain a mean arterial blood pressure of 65 to 90 mm Hg, and red blood cell transfusions or inotropes to attain a central venous oxygen saturation of at least 70% did not decrease mortality compared with unstructured clinical care (24.9% vs 25.4%; P = .68). Among 1563 patients with sepsis and hypotension who received 1 L of fluid, an RCT reported that favoring vasopressor treatment did not improve mortality compared with further fluid administration (14.0% vs 14.9%; P = .61). Another RCT reported that among 1554 patients in the intensive care unit with septic shock treated with at least 1 L of fluid compared with more liberal fluid administration, restricting fluid administration in the absence of severe hypoperfusion did not reduce mortality (42.3% vs 42.1%; P = .96). An RCT of 1000 patients with acute respiratory distress during the evacuation phase reported that limiting fluid administration and administering diuretics improved the number of days alive without mechanical ventilation compared with fluid treatment to attain higher intracardiac pressure (14.6 vs 12.1 days; P < .001), and it reported that hydroxyethyl starch significantly increased the incidence of kidney replacement therapy compared with saline (7.0% vs 5.8%; P = .04), Ringer lactate, or Ringer acetate.
Fluids are an important component of treating patients who are critically ill with sepsis. Although optimal fluid management in patients with sepsis remains uncertain, clinicians should consider the risks and benefits of fluid administration in each phase of critical illness, avoid use of hydroxyethyl starch, and facilitate fluid removal for patients recovering from acute respiratory distress syndrome.
大约 20%至 30%入住重症监护病房的患者患有败血症。虽然液体疗法通常在急诊科开始,但重症监护病房中的静脉输液是治疗败血症的重要组成部分。
对于败血症患者,静脉补液可以增加心输出量和血压,维持或增加血管内液体量,并输送药物。液体疗法可以从早期疾病到败血症缓解的 4 个重叠阶段来概念化:复苏(快速补液以恢复灌注);优化(评估额外液体治疗休克和确保器官灌注的风险和益处);稳定(只有在有液体反应性信号时才使用液体疗法);和清除(在治疗危重病时积累的多余液体被清除)。在接受 1 至 2 升液体的 3723 名败血症患者中,3 项随机临床试验 (RCT) 报告说,目标导向治疗给予液体冲击以达到中心静脉压 8 至 12 mmHg,给予加压素以达到平均动脉血压 65 至 90 mmHg,以及红细胞输注或正性肌力药物以达到至少 70%的中心静脉血氧饱和度,与非结构化临床护理相比并未降低死亡率(24.9% 对 25.4%;P=0.68)。在接受 1 升液体的 1563 名败血症低血压患者中,一项 RCT 报告说,与进一步给予液体相比,选择加压素治疗并未改善死亡率(14.0% 对 14.9%;P=0.61)。另一项 RCT 报告说,与更自由的液体管理相比,在重症监护病房接受至少 1 升液体治疗的 1554 名败血症性休克患者中,在没有严重低灌注的情况下限制液体管理并未降低死亡率(42.3% 对 42.1%;P=0.96)。在撤离阶段对 1000 名急性呼吸窘迫患者进行的 RCT 报告说,与液体治疗以达到更高的心内压相比,限制液体管理和给予利尿剂可改善无机械通气存活天数(14.6 天对 12.1 天;P<0.001),并且报告羟乙基淀粉显著增加了与生理盐水(7.0%对 5.8%;P=0.04)、乳酸林格氏液或醋酸林格氏液相比肾替代治疗的发生率。
液体是治疗患有败血症的危重病患者的重要组成部分。尽管败血症患者的最佳液体管理仍不确定,但临床医生应考虑在危重病的每个阶段给予液体的风险和益处,避免使用羟乙基淀粉,并促进急性呼吸窘迫综合征患者的液体清除。